Between 2005 and 2015, bacterial sexually transmitted infections (BSTIs) have markedly increased among men who have sex with men (MSM) \[[@CIT0001]\]. Previously, BSTI were associated with increased likelihood of HIV spread in MSM, with BSTI trends considered surrogates for HIV transmission risk \[[@CIT0005]\]. However, this association has been altered, given data supporting earlier initiation of treatment for HIV-infected people \[[@CIT0006], [@CIT0007]\], with associated virologic suppression decreasing HIV transmission risk \[[@CIT0008], [@CIT0009]\]. Additionally, the evidence that antiretroviral pre-exposure prophylaxis (PrEP) can decrease HIV incidence \[[@CIT0010]\] has uncoupled the relationship between condomless sex and HIV acquisition. Concerns have been raised that HIV-infected individuals who are virologically suppressed and high-risk uninfected people adherent to PrEP are likely to decrease condom use, resulting in increasing BSTI rates \[[@CIT0016]\].

To better understand secular trends in BSTI and the contribution of HIV-infected individuals and high risk HIV-uninfected MSM using HIV PrEP to increasing rates of BSTI, we analyzed data from an open cohort of MSM accessing primary care at a Boston community health center with expertise in the care of sexual and gender minority populations \[[@CIT0020]\]. Since 1997, the community health center has used a standardized electronic health record using consistent data variables. The health center has been the largest HIV primary care practice in Massachusetts and has diagnosed the greatest number of BSTIs among MSM at a single site in New England. The center has conducted PrEP research for more than a decade \[[@CIT0010], [@CIT0021]\] and has the largest PrEP program in New England, and is thus well suited to evaluate associations of HIV treatment and prevention advances on BSTI trends.

METHODS {#s1}
=======

Study Population {#s2}
----------------

We followed an open cohort of MSM receiving primary care in order to look at the absolute numbers and rates of new infections and the sociodemographic and behavioral correlates of those who were becoming infected with BSTI. This study included male patients accessing medical services at an urban federally qualified community health center serving more than 30 000 patients. Patients included in the sample were cisgender MSM (ie, male at birth and no indication of transgender or gender nonconforming identity), with at least 1 medical visit during the study period (January 1, 2005, through December 31, 2015). Since 2011, sexual orientation has been systematically recorded in the electronic health record (EHR) as a standardized variable, based on patient self-report during registration. Efforts have been made to update this information for patients registered prior to 2011, but this information is incomplete, especially for patients with infrequent or discontinued care. Therefore, to create the cohort, we assumed patients were MSM if (1) sexual orientation was recorded as gay or bisexual or (2) sexual orientation characterization was not recorded as heterosexual and laboratory records indicated prior examination for rectal or pharyngeal BSTI.

Data Collection {#s3}
---------------

Data were abstracted from the health center's electronic health record (GE Healthcare Centricity Practice Solution), which was implemented in 1997. The EHR includes all registration, encounter, clinical, sociodemographic, and billing information. Patient data were electronically extracted using Structured Query Language (SQL). Data extracted from the EHR included date of birth, sex at birth, gender identity, legal sex, sexual orientation, race/ethnicity, insurance status (on the date of data collection), HIV diagnoses (onset date), PrEP prescription records (dates prescribed and terminated), BSTI laboratory data (date and results of screening), and date of medical visits. SAS version 9.4 was used for all analyses.

BSTI Diagnoses {#s4}
--------------

BSTI laboratory data were automatically imported, and SQL was used to extract test results, test types, and dates from discrete observation fields. Because several different diagnostic tests were used to detect gonorrhea and chlamydia over the course of the observation period (ie, polymerase chain reaction, transcription-mediated amplification, branched DNA, and gonococcal cultures), results were abstracted and recoded to uniformly indicate positive, negative, or indeterminate by anatomical site. Based on clinic protocols, we assumed that gonorrhea and chlamydia infections were adequately treated and considered subsequent infections in the same anatomical site as new, independent events. New syphilis infections were defined as the first reactive serological response of an rapid plasma reagin or Venereal Disease Research Laboratory, confirmed by an fluorescent treponemal antibody absorption test test, following at least 1 nonreactive result, or any change in titer response that was at least 4-fold greater than the previous screening, after appropriate antibiotic treatment, based on the Centers for Disease Control and Prevention Sexually Transmitted Disease Treatment Guidelines, 2015 \[[@CIT0022]\]. The detection of syphilis and/or gonorrhea or chlamydia in multiple anatomical sites in 1 person on the same date was considered 1 infection for respective measurements of disease-specific occurrence.

HIV Serostatus and PrEP Use {#s5}
---------------------------

We used the International Classification of Diseases (ICD) condition codes (ICD-9 and ICD-10: 042, V08, B20 and Z21) maintained by the World Health Organization to determine HIV status and clinician assigned date of seroconversion if HIV was diagnosed during the study period. Patients were assumed to be HIV-uninfected if no ICD code for HIV appeared in their EHR. To identify use of PrEP among HIV-uninfected patients, we searched prescription records for tenofovir-emtricitabine (and no third antiretroviral medication) that was prescribed for periods greater than 28 days (to exclude use as postexposure prophylaxis). For the purpose of this analysis, we assumed patients initiated PrEP if prescribed, and these patients were classified as PrEP users for the remainder of the study period.

Statistical Analyses {#s6}
--------------------

In crude analyses, chi-square tests \[[@CIT0023]\] were used to compare characteristics of the subsample of patients with any BSTI during the study period with those with none; similarly, we stratified and compared patients by HIV serostatus and PrEP use at the end of the study period. Incidence rates of BSTI were calculated at 4-month intervals and were calculated seperately for HIV status, PrEP use, age category, race, and insurance status. To determine the size of the health center's MSM population and the distribution of demographics during each interval, patients contributed 4 months of person-time to any interval of which either a medical visit or laboratory screening for BSTI occurred. If the clinical encounter was the patient's first visit to the health center, person-time began on the date of the visit and accrued for the remainder of the interval. Person-time and BSTI frequency were aggregated for each combination of time interval and the demographic variables.

Insurance status and race/ethnicity were fixed for the entire study period, while age, HIV status, and PrEP use were time-varying. Age category was calculated on the midpoint of each time interval and held fixed for the entire interval. HIV status and PrEP use varied according to the date of seroconversion or PrEP initiation, respectively, such that patients contributed person-time according to their HIV status and PrEP use, proportional to the periods before and after the date of change. Any BSTIs diagnosed on the date of seroconversion or PrEP initiation were attributed to the period before the status change. Poisson regression \[[@CIT0024]\] was used for multivariable analysis of BSTI diagnosis incidence, with time included as 2 continuous linear variables (2005--2009 and 2010--2015, inclusive), and HIV status, PrEP use, age category, race, and insurance status included categorically. Based on visual inspection of [Figure 1](#F1){ref-type="fig"}, we used piecewise linear regression to model the longitudinal trend in diagnosis rate \[[@CIT0025]\]. A spline knot between 2009 and 2010 allowed us to estimate separate slopes for 2005--2009 and 2010--2015. Crude and adjusted analyses were restricted to patients (n = 15 617) with available race/ethnicity and insurance information. Interaction was explored for age group and insurance status as well as age group and race. The observed effects were small in magnitude, so final regression models are restricted to main effects only.
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RESULTS {#s7}
=======

Between 2005 and 2015, 19 232 cis-gender men had at least 1 clinic visit ([Table 1](#T1){ref-type="table"}), of whom 3355 were only seen once. Most male patients (72.4%) seen during this time interval were white, 6.0% were black, and 6.1% were Latino. Although 42.6% of the male patients described themselves as gay and 3.2% as bisexual, 52.5% did not report their sexual orientation. The majority (61.7%) had private health insurance, 5.4% had Medicare, 4.6% had Medicaid, 8.4% reported no insurance, and for 16% insurance status was unknown ([Table 1](#T1){ref-type="table"}). The overall diagnosed HIV prevalence in the MSM population of the health center over the course of the study was 15.4%. Between 2005 and 2015, the clinic census of HIV-infected primary care patients doubled to 2085, with virologic suppression rates reaching 86% by 2015 (data not shown). In 2011, 5 patients initiated PrEP as part of medical care (outside of the context of a clinical trial), compared with 960 in 2015. By 2015, 10.1% of HIV-uninfected MSM in primary care at the community health center had been prescribed PrEP.

###### 

Sociodemographic Characteristics of Men Accessing Primary Care at a Boston Community Health Center

  Characteristic, n (%)       All patients          BSTI Diagnosis^a^   Final HIV and PrEP Use Status^b^                                                                        
  --------------------------- -------------- ------ ------------------- ---------------------------------- ------ ------- --------- ------ ------ -------- ------ ------ ------ ---------
  No. of patients             19 232                16 114                                                 3118                     2968          14 633          1631          
  Age at entry to cohort, y                                                                                               \<.0001                                               \<.0001
   12--17                     47             0.2    39                  0.24                               8      0.26              0      0.0    24       0.16   0      0.0    
   18--24                     4195           21.8   3431                21.3                               764    24.5              113    3.8    2503     17.1   190    11.7   
   25--34                     6355           33.0   5173                32.1                               1182   37.9              535    18.0   4879     33.3   718    44.0   
   35--44                     4601           23.9   3828                23.76                              773    24.79             726    24.5   2836     19.4   368    22.6   
   45+                        4034           21.0   3643                22.6                               391    12.5              1594   53.7   4391     30.0   355    21.8   
  Race                                                                                                                    \<.0001                                               \<.0001
   White                      13 917         72.4   11749               72.9                               2168   69.5              2090   70.4   10 628   72.6   1199   73.5   
   Black                      1153           6.0    896                 5.6                                257    8.2               292    9.8    771      5.3    90     5.5    
   Latino                     1179           6.1    945                 5.9                                234    7.5               249    8.4    848      5.8    82     5.0    
   Asian                      897            4.7    772                 4.8                                125    4.0               87     2.9    735      5.0    75     4.6    
   Multiracial/other          1112           5.8    845                 5.2                                267    8.6               225    7.6    725      5.0    162    9.9    
   Not reported               974            5.1    907                 5.6                                67     2.2               25     0.8    926      6.3    23     1.4    
  Sexual orientation                                                                                                      \<.0001                                               \<.0001
   Gay                        8201           42.6   6407                39.8                               1794   57.5              1464   49.3   5546     37.9   1191   73.0   
   Bisexual                   615            3.2    523                 3.3                                92     3.0               70     2.4    497      3.4    48     2.9    
   Don't know/other           323            1.7    255                 1.6                                68     2.2               60     2.0    226      1.5    37     2.3    
   Not reported               10 093         52.5   8929                55.4                               1164   37.3              1374   46.3   8364     57.2   355    21.8   
  Insurance                                                                                                               \<.0001                                               \<.0001
   Private                    11 861         61.7   9571                59.4                               2290   73.4              1533   51.7   8842     60.4   1486   91.1   
   Medicare                   1044           5.4    908                 5.6                                136    4.4               487    16.4   530      3.6    27     1.7    
   Medicaid                   886            4.6    680                 4.2                                206    6.6               342    11.5   497      3.4    47     2.9    
   None                       1615           8.4    1479                9.2                                136    4.4               286    9.6    1307     8.9    22     1.4    
   Other                      751            3.9    594                 3.7                                157    5.0               201    6.8    502      3.4    48     2.9    
   Unknown                    3075           16.0   2882                17.9                               193    6.2               119    4.0    2955     20.2   1      0.1    

Abbreviations: BSTI, bacterial sexually transmitted infection; PrEP, pre-exposure prophylaxis.

^a^2005--2015.

^b^HIV status and PrEP use defined on the date of last patient contact during the study period.

Between 2005 and 2015, the annual number of BSTIs diagnosed at Fenway Health increased from 157 to 1319 ([Table 2](#T2){ref-type="table"}), with syphilis diagnoses increasing from 58 to 241 cases, gonorrhea from 40 to 554 cases, and chlamydia from 91 to 679 cases. In 2015, 13.9% of the HIV-infected male patients and 24.8% of male HIV-uninfected patients prescribed PrEP were diagnosed with at least 1 BSTI. The diagnosis rate of an MSM patient being diagnosed with a BSTI increased from 4.6 to 26.8 per 100 person-years between 2005 and 2015 ([Figure 1](#F1){ref-type="fig"}). During the same time period, the overall volume of BSTI screening (unique tests per 100 patient-years) also increased ([Figure 2](#F2){ref-type="fig"}). The magnitude of increased screening among HIV-infected patients and HIV-uninfected patients not accessing PrEP was modest, with the rate of BSTI screening (frequency of clinical visits in which at least 1 BSTI test was ordered) increasing from 140 to 211 BSTI visits per 100 person-years between 2005 and 2015 for HIV-infected MSM and 107 to 170 for HIV-uninfected MSM who were not using PrEP. Patients accessing PrEP had a much higher total volume of screening (increasing from 247 to 322 BSTI visits per 100 person-years over 4 years). The relative contribution of PrEP patients to the number of BSTI visits and diagnoses increased at the same time as the total number of patients accessing PrEP also increased in recent years ([Figures 3](#F3){ref-type="fig"} and [4](#F4){ref-type="fig"}).

###### 

Frequency of Bacterial STIs and Proportion Identified Among Patients HIV-Infected, HIV-Uninfected, or HIV-Uninfected and Using PrEP in the Years 2005 and 2015

                2005   2015                                 
  ------------- ------ ------- ------- ------ ------ ------ ------
  Any BSTI^b^   157    38.2    61.8    1319   22.7   44.5   32.8
  Syphilis      58     67.2    32.8    241    44.8   29.5   25.7
  Gonorrhea     40     32.5    67.5    554    20.0   46.6   33.4
   Urogenital   39     33.3    66.7    172    19.2   46.5   34.3
   Rectal       0      \-\--   \-\--   285    21.4   45.3   33.3
  Chlamydia     91     20.9    79.1    679    18.7   45.8   35.5
   Urogenital   91     20.9    79.1    233    13.3   54.1   32.6
   Rectal       0      \-\--   \-\--   469    21.5   40.7   37.7

Abbreviations: BSTI, bacterial sexually transmitted infection; PrEP, pre-exposure prophylaxis.

^a^Frequency of infections diagnosed in male patients accessing care during the calendar year.

^b^Diagnoses of more than 1 infection or the same infection in more than 1 anatomical site in a single patient on the same day were considered 1 infection for any BSTI.

![Screening rate (unique patient visits) of bacterial sexually transmitted infection stratified by HIV serostatus and pre-exposure prophylaxis use (2005--2015). Abbreviations: BSTI, bacterial sexually transmitted infection; PrEP, pre-exposure prophylaxis.](ofx21402){#F2}

![Diagnosis rate (unadjusted) of bacterial sexually transmitted infection stratified by HIV serostatus and pre-exposure prophylaxis use (2005--2015). Abbreviation: PrEP, pre-exposure prophylaxis.](ofx21403){#F3}

![(A) Frequency of any bacterial sexually transmitted infection (BSTI) and distribution by HIV status and pre-exposure prophylaxis (PrEP) use among men who have sex with men (MSM) patients at a Boston community health center. **(B)** Frequency of syphilis infections and distribution by HIV status and PrEP use among MSM patients at a Boston community health center. **(C)** Frequency of gonnorhea infections and distribution by HIV status and PrEP use among MSM patients at a Boston community health center. **(D)** Frequency of chlamydia infections and distribution by HIV status and PrEP use among MSM patients at a Boston community health center. Abbreviation: PrEP, pre-exposure prophylaxis.](ofx21404){#F4}

In 2015, 44% of syphilis diagnoses were among HIV-infected patients, while HIV prevalence among patients diagnosed with gonorrhea was 20%, and 19% for chlamydia ([Table 2](#T2){ref-type="table"}). The majority of patients who were diagnosed with BSTI were white ([Table 1](#T1){ref-type="table"}), although the BSTI prevalence among black and Latino male patients was significantly greater than their representation among patients engaged in medical care at the health center. In 2015, the mean age of BSTI patients was 41.3 years (SD = 13 years). Patients older than age 45 years contributed the most person-time to the study, reflecting the distribution of age in the sample ([Table 3](#T3){ref-type="table"}). Although many male patients diagnosed with a BSTI did not disclose their sexual orientation, 57.3% identified as gay. The majority of BSTI patients (72.1%) had private health insurance ([Table 1](#T1){ref-type="table"}). After exclusion of patients missing race/ethnicity or insurance information, there were no meaningful differences between the analysis sample and the original sample ([Table 3](#T3){ref-type="table"}).

###### 

Frequency of Bacterial STI Diagnosis and Person-time Contribution

                             Total Sample   Analysis Sample^a^                           
  -------------------------- -------------- -------------------- ------- ------ -------- -------
  Total                      5207           42 412               12.28   4931   40 183   12.27
  HIV status                                                                             
   HIV-infected              1629           11 596               14.05   1616   11 483   14.07
   HIV-uninfected, no PrEP   2918           29 486               9.90    2668   27 382   9.74
   HIV-uninfected, PrEP      660            1331                 49.59   647    1318     49.09
  Age group, y                                                                           
   12--17                    2              17                   11.76   2      11       18.18
   18--24                    725            2830                 25.62   642    2280     28.16
   25--34                    1950           9776                 19.95   1844   8993     20.50
   35--44                    1333           11 470               11.62   1283   11 043   11.62
   45+                       1197           18 319               6.53    1160   17 857   6.50
  Race/ethnicity                                                                         
   Asian                     178            1283                 13.87   166    1194     13.90
   Black                     461            2220                 20.77   435    2119     20.53
   Multiracial/other         427            1956                 21.83   417    1933     21.57
   Latino                    387            2465                 15.70   371    2342     15.84
   White                     3664           33 649               10.89   3542   32 594   10.87
   Not reported              90             840                  10.71   0      0        \--
  Insurance                                                                              
   Private                   3862           30 254               12.77   3811   29 831   12.78
   Medicare                  274            5048                 5.43    274    5011     5.47
   Medicaid                  387            2087                 18.54   386    2053     18.80
   None                      191            2246                 8.50    183    2134     8.58
   Other                     281            1203                 23.36   277    1154     24.00
   Unknown                   212            1576                 13.45   0      0        \--

Abbreviations: BSTI, bacterial sexually transmitted infection; PrEP, pre-exposure prophylaxis.

^a^Excludes patients missing information on race/ethnicity and/or insurance.

A multivariable analysis was performed to assess independent predictors of BSTI diagnosis ([Table 4](#T4){ref-type="table"}). Relative to HIV-uninfected MSM not using PrEP, HIV-infected men had an adjusted diagnosis rate ratio (aDRR) of 1.83 (95% CI, 1.72--1.96) and HIV-uninfected PrEP users had an aDRR of 2.36 (95% CI, 2.15--2.59) for BSTI acquisition. Other variables associated with an increased rate of BSTI diagnoses were black race (aDRR, 1.34; 95% CI, 1.21--1.49) or multiracial background (aDRR, 1.19; 95% CI, 1.08--1.32). Insurance status also was associated with a diagnosis of BSTI, with Medicaid recipients having an aDRR of 1.22 (95% CI, 1.09--1.35) and those with Medicare having an aDRR of 0.60 (95% CI, 0.53--0.68) compared with those with private insurance. There also was a time trend in the diagnoses of BSTI, with the rate of BSTI diagnoses increasing by 5% each year from 2005--2009 (95% CI, 2%--9%) and 22% each year from 2010--2015 (95% CI, 13%--33%). Among HIV-infected MSM, the adjusted diagnosis rate of BSTI was 16.28 per 100 person-years in 2011, compared with 33.71 per 100 person-years in 2015, an increase of 17.43. For HIV-uninfected MSM, the diagnosis rate increased 19.22 from 6.65 to 25.87 per 100 person-years over the same time period.

###### 

Diagnosis Rate Ratio for Men Being Diagnosed with a Bacterial STI at a Boston Community Health Center, 2005--2015

  HIV Status          Crude Models   Multivariable^a^ Model                                                                      
  ------------------- -------------- ------------------------ ------- ------ ------ ------ ------- ------- ------- ------ ------ ------
  HIV+                14.07          13.40                    14.78   1.44   1.36   1.54   19.04   14.31   25.33   1.83   1.72   1.96
  HIV-, no PrEP       9.74           9.38                     10.12   Ref                  10.39   7.82    13.80   Ref           
  HIV-, PrEP          49.11          45.47                    53.04   5.04   4.63   5.49   24.55   18.27   32.99   2.36   2.15   2.59
  Age group, y                                                                                                                   
  12--17              18.95          4.74                     75.77   0.67   0.17   2.70   19.66   4.91    78.78   0.66   0.16   2.65
  18--24              20.51          19.59                    21.46   Ref                  29.78   27.03   32.80   Ref           
  25--34              11.62          11.00                    12.27   0.73   0.67   0.80   22.04   20.43   23.78   0.74   0.68   0.81
  35--44              6.50           6.13                     6.88    0.41   0.38   0.45   14.41   13.25   15.66   0.48   0.44   0.53
  45+                 28.16          26.06                    30.42   0.23   0.21   0.25   7.49    6.84    8.20    0.25   0.23   0.28
  Race                                                                                                                           
  Asian               13.90          11.94                    16.18   1.28   1.09   1.49   13.57   9.85    18.69   0.87   0.74   1.02
  Black               20.53          18.69                    22.55   1.89   1.71   2.09   20.93   15.58   28.12   1.34   1.21   1.49
  Multiracial/other   21.57          19.59                    23.74   1.98   1.79   2.20   18.58   13.84   24.94   1.19   1.08   1.32
  Latino              15.84          14.31                    17.54   1.46   1.31   1.62   16.94   12.57   22.82   1.09   0.98   1.21
  White               10.87          10.51                    11.23   Ref                  15.58   11.73   20.69   Ref           
  Insurance                                                                                                                      
  Medicaid            18.80          17.02                    20.78   1.47   1.33   1.63   20.68   15.40   27.76   1.22   1.09   1.35
  Medicare            5.47           4.86                     6.16    0.43   0.38   0.48   10.19   7.51    13.85   0.60   0.53   0.68
  None                8.58           7.42                     9.91    0.67   0.58   0.78   17.06   12.43   23.41   1.00   0.86   1.17
  Other               24.00          21.33                    27.00   1.88   1.66   2.12   22.78   16.81   30.87   1.34   1.18   1.52
  Private             12.78          12.38                    13.19   Ref                  17.00   12.80   22.57   Ref           
  Time trend^c^                                                                                                                  
  2005--2009          \-\--                                           1.01   0.98   1.05   \-\--                   1.05   1.02   1.09
  2010--2015          \-\--                                           1.28   1.18   1.39   \-\--                   1.22   1.13   1.33

Abbreviations: BSTI, bacterial sexually transmitted infection; DR, diagnosis rate; DRR, diagnosis rate ratio; PrEP, pre-exposure prophylaxis.

^a^Adjusted for all other covariates in the model.

^b^Diagnosis rate per 100 person-years.

^c^One-year increments.

We considered 2 scenarios where bias in the data could be generating our results. First, to assess whether missing sexual orientation information prior to 2011 could bias diagnosis rates of BSTIs, we performed a sensitivity analysis of the multivariable model (data not shown) by stratifying the sample to compare subjects with recorded sexual orientation with those without. The time trend in diagnosis rate was the same for both groups of MSM. Second, we considered whether infections diagnosed on a patient's first medical visit could bias the results if episodic BSTI screening changed over time. We excluded such cases for a sensitivity analysis (data not shown) and found the results, including the time trend, to be unchanged.

DISCUSSION {#s8}
==========

This study found an increasing rate of BSTI diagnoses among MSM accessing care in a Boston community health center between 2005 and 2015, reflecting national trends \[[@CIT0002]\]. Some have attributed the recent increase in BSTI primarily to PrEP use \[[@CIT0016]\], but the current data derived from a regional center specializing in care of MSM \[[@CIT0020]\] suggest that the factors associated with increasing BSTI among MSM are more complex and multifaceted, as increases in BSTI were also seen in HIV-infected MSM and HIV-uninfected MSM not using PrEP. Part of the explanation for the increased detection of BSTIs in MSM is that screening rates increased significantly over the decade ([Figure 2](#F2){ref-type="fig"}). However, this does not fully explain the findings in this study for several reasons: the secular trends in diagnosis rates were seen independently in HIV-infected and HIV-uninfected MSM who were not using PrEP, as well as PrEP patients, even though overall screening rates did not increase greatly among MSM in the first 2 categories, and the secular trend toward increasing BSTI rates began before 2010, even though screening rates did not significantly increase until 2013. Another factor that may explain the increased BSTI screening rates is that the care setting was a federally qualified community health center in a state that embraced health insurance reforms more than a decade ago. Ryan-White funds supported BSTI screening for HIV-infected patients, and almost all of the HIV-uninfected individuals had access to health insurance.

However, there were subgroup differences in screening and diagnosis rates among the MSM. Individuals who accessed PrEP were most likely to be diagnosed with a new BSTI, with a diagnosis rate ratio of 2.36 compared with those who were not PrEP users, similar to several recent reports in other care centers \[[@CIT0017], [@CIT0018]\]. The detection of increasing BSTI diagnoses among PrEP-using MSM underscores the importance of routine BSTI screening of MSM PrEP users \[[@CIT0026]\]. The higher BSTI prevalence in PrEP users may reflect ascertainment biases because of their increased frequency of asymptomatic routine screening compared with MSM not engaged in PrEP care.

HIV-infected MSM also had an increased incidence rate ratio for BSTI diagnoses compared with HIV-uninfected MSM who were not using PrEP, suggesting that PrEP has not been the sole driver of increasing BSTIs among MSM. PrEP was only introduced into clinical care in 2011, but the increasing rates of BSTIs among HIV-infected MSM began earlier in the decade. Even after adjusting for HIV status and PrEP use, the longitudinal trend of increasing BSTI diagnoses remained significant in the analysis. Overall BSTI rates were lowest for HIV-uninfected MSM who were not using PrEP, but as they were the majority of MSM clinic patients, their BSTI burden represents a major contribution to the number of infections. The absolute associations of PrEP and HIV serostatus with community BSTI burden can best be determined in prospective cohort studies using uniform screening protocols.

The trend toward increased BSTI rates among HIV-infected MSM might reflect serosorting, ie, selecting only other HIV-infected partners, in order to engage in condomless intercourse without concern about transmitting HIV to new partners \[[@CIT0026]\], though it may also reflect an increased willingness to engage in condomless sex with partners of any serostatus. Almost all of this clinic's HIV-infected patients were virologically suppressed, and they may have felt that they were unlikely to transmit HIV \[[@CIT0027], [@CIT0028]\], which is supported by multiple studies \[[@CIT0006], [@CIT0007], [@CIT0029]\]. The data in the current study support the importance of routine BSTI screening as part of HIV primary care, in conjunction with support for antiretroviral medication adherence.

This study also found that BSTIs were also rising among HIV-uninfected MSM who were not using PrEP. This last group of individuals deserves particular attention because, in addition to having acquired a BSTI, by not accessing PrEP they are particularly vulnerable to HIV seroconversion \[[@CIT0030], [@CIT0031]\]. It will be important to better understand why these individuals did not avail themselves of PrEP, given their increased risk for HIV. Although black and multiracial MSM constituted a minority of the male clinic patients, they were much more likely to acquire a new BSTI than other MSM, even when controlling for other variables. About one-fourth of all new HIV infections in the United States are diagnosed in black MSM, although they constitute less than 1% of the US population and are often economically disenfranchised \[[@CIT0032], [@CIT0033]\], impeding access to preventive care services. Because of their disproportionate HIV and BSTI incidence, strategies to engage black and other racial and ethnic minority MSM to increase STI screening, HIV status awareness, and access to prompt treatment or PrEP are needed to stem the spread of HIV in these communities. Individuals who were insured by Medicaid were more likely to acquire BSTIs than those with private insurance in the current study ([Table 4](#T4){ref-type="table"}). It is conceivable that not having private health insurance may reflect social and structural adversities, such as being unemployed, and/or being a recent migrant to the state or the United States. It is feasible that programs focused on addressing these issues could ensure prompt and timely access to sexual health services, leading to earlier diagnoses and treatment, decreasing further transmission.

In summary, these data document a marked increase in the rate of new BSTIs between 2005 and 2015 in a Boston community health center. However, the data also suggest that the reasons for increasing BSTI rates in this population are complex and multifactorial. The data should be carefully interpreted, as the analyses were based on an open cohort; ie, individuals had variable lengths of follow-up and were not part of a uniform screening protocol, compared with a prospective cohort study, in which the frequency of screening would be prespecified. Hence, provider and patient behavior could introduce unmeasured confounding. Changes in screening practices over the decade could have led to ascertainment biases. HIV-infected patients and those using PrEP were screened more regularly as part of the clinical monitoring, while HIV-uninfected MSM who were not using PrEP had fewer reasons to seek ongoing care and were screened less often for BSTIs. Estimates of BSTI incidence may also be imprecise if some individuals were managed syndromically and did not have corroborative lab assays performed, although this practice was not common in this clinic.

The increased BSTI diagnoses among PrEP users may be due to risk compensation, but it may also reflect increased routine screening. At the same time, the majority of people who developed a BSTI were not on PrEP. These data suggest that individuals who are HIV-infected and virologically suppressed should be reminded of their vulnerability to acquiring and transmitting BSTIs. This study also documented a substantial number of HIV-uninfected MSM who had BSTIs and who were not on PrEP, and who remain at high risk for HIV seroconversion. The findings from the current study suggest that ongoing PrEP education and integration with BSTI diagnostic and treatment services remain an important priority, with particular attention needed in developing programs that are culturally tailored to engage black and other racial and ethnic minority MSM that address social and structural challenges to accessing this preventive intervention. Routine sexual health counseling as part of the care for MSM is exceedingly important, as evinced by the study data, given high rates of diagnosed BSTIs in HIV-infected and -uninfected MSM.
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